Antiangiogenic effects of PI3K inhibitor NVP-BKM120.

Slides:

Advertisements

Similar presentations

AF647-RIS is internalized by TAMs in vivo.

Advertisements

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers. XL184 effects on RIP-Tag2 tumor invasion and epithelial/mesenchymal markers.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

CCL5 is critical for the activity of CAFs and miR-CAFs.

Pten deficiency induces strong stromal reaction with immune cell infiltration and promotes the development of invasive and metastatic pancreatic tumors.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

T1D is reduced in CT-treated NOD mice.

Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination with olaparib. Antitumor efficacy of PI3K inhibitor NVP-BKM120 alone and in combination.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Characteristics of spontaneous HPV buccal tumors.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

mTORC1 is required to prevent cellular senescence.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

Amppos tumors are a distinct tumor subpopulation.

In vivo thrombosis of tumor vasculature.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Vascular staining in CWR22R xenograft tumors.

A, TSG-6 staining in TRAMP tissue and TRAMP cell lines.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

5FU-induced specific activation of CD8+ T cells.

CD4+ and CD8+ TILs express surface CD137.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Circulating leukocytes are undetectable in blood vessels of solid tumors in RIP1-Tag2 mice even after IL-15/IL-15Rα complex treatment. Circulating leukocytes.

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

HMQ1611 inhibited breast tumor growth in mice.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

The effect of a DIO regimen ± EPA+DHA supplementation on tumor growth.

GATA-3 immunostaining was scored semiquantitatively; tumors with

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Increased expression of angiogenic factors and inflammatory cytokines in mice exposed to hypoxia. Increased expression of angiogenic factors and inflammatory.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

BMX is a driver of castration resistance in vitro and in vivo.

Levels of neutrophil infiltration into gliomas correlate with tumor grades and tumor progression. Levels of neutrophil infiltration into gliomas correlate.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

AR promotes DNA double-strand break resolution.

GCS-100 selectively kills KRAS-addicted lung tumors.

VEGF-A inhibition impedes proliferation in Amppos tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. AXL-on tumors are heterogeneous for AXL expression and EdU incorporation. A,

Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

CD36 expression in tissue adjacent and distal to the tumor.

TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3 pathway. TAMs upregulate DNMT1 in gastric cancer cells through the CCL5/CCR5/STAT3.

PEGPH20 depletes HA and decompresses intratumoral vessels.

Comparison of PD-L1 mAbs in IHC across multiple tumor types.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

MITF-low/NF-κB–high transcriptional class is present and associated with resistance to MAPK pathway inhibition in human tumors. MITF-low/NF-κB–high transcriptional.

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

Presentation transcript:

Antiangiogenic effects of PI3K inhibitor NVP-BKM120. Antiangiogenic effects of PI3K inhibitor NVP-BKM120. A, gross pathologic images of an untreated tumor (left), a tumor treated for 2 weeks (middle), and a tumor treated for 6 weeks (right) with NVP-BKM120 at 50 mg/kg/d via gavage. IHC to detect CD31 in an untreated tumor (B), the center of a tumor treated for 6 weeks (C), and the tumor capsule of a mammary tumor treated for 6 weeks (D). E, determination of the Chalkley score to quantify CD31 staining. IHC with anti-CD31 antibodies was conducted in pretreatment biopsies and in tumor specimens from mice at the time of tumor progression. Ashish Juvekar et al. Cancer Discovery 2012;2:1048-1063 ©2012 by American Association for Cancer Research